Management of the aortic arch in patients with syndromic heritable thoracic aortic disease

综合征型遗传性胸主动脉疾病患者的主动脉弓管理

阅读:4

Abstract

OBJECTIVES: The aim of this study was to examine the evolution of the aortic arch over time in patients with HTAD. METHODS: We screened all patients with Marfan syndrome (MFS) or Loeys-Dietz syndrome (LDS) who were seen at our HTAD clinic since 1995. Patients who had undergone aortic surgery were included in the present study. Patients were analysed based on (1) extent of aortic arch replacement, (2) history of aortic dissection and (3) outcome after secondary total aortic arch replacement (TAR). RESULTS: A cohort of 260 patients was identified of whom 165 patients with MFS (n = 138) and LDS (n = 27) had already undergone aortic surgery and were included in this study. LDS: initial presentation was acute aortic dissection (AAD) in five (19%) patients, while 22 (81%) patients presented with aneurysmal disease. Only two patients required secondary TAR during follow-up. MFS: initial presentation was AAD in 41 (30%) patients, while 97 (70%) presented with aneurysmal disease. Only 3% (n = 3) of the MFS patients without primary aortic arch replacement required a secondary TAR. There was significantly more secondary TAR in MFS patients with history of aortic dissection compared to those without (P = 0.019). However, there was no significant differences in rate of downstream aortic events in MFS patients with secondary TAR compared to those without (P = 0.089). There was no significant difference in mortality in MFS patients with secondary TAR compared to those without (P = 0.366). CONCLUSIONS: Concomitant prophylactic TAR in MFS patients undergoing elective root repair is not justified. One out of four MFS patients with history of AAD will have to undergo secondary TAR during follow-up. MFS patients undergoing secondary TAR do not have worse survival compared to those without. Current data do not provide enough evidence for strong recommendations regarding the need for prophylactic aortic arch replacement in LDS patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。